Viracta Therapeutics, Inc. (NASDAQ:VIRX – Get Rating)’s share price fell 11% on Monday . The company traded as low as $0.88 and last traded at $0.89. 132,839 shares changed hands during mid-day trading, an increase of 63% from the average session volume of 81,580 shares. The stock had previously closed at $1.00.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on VIRX. Royal Bank of Canada restated an “outperform” rating and issued a $8.00 target price on shares of Viracta Therapeutics in a report on Tuesday, March 14th. Oppenheimer boosted their target price on shares of Viracta Therapeutics from $14.00 to $16.00 and gave the stock an “outperform” rating in a report on Monday, March 27th. Finally, HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Viracta Therapeutics in a report on Tuesday, March 14th.
Viracta Therapeutics Price Performance
The company has a market capitalization of $34.18 million, a P/E ratio of -0.68 and a beta of 1.20. The firm’s fifty day moving average is $1.46 and its 200 day moving average is $2.01. The company has a debt-to-equity ratio of 0.45, a quick ratio of 9.36 and a current ratio of 9.36.
Hedge Funds Weigh In On Viracta Therapeutics
About Viracta Therapeutics
Viracta Therapeutics, Inc a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas.
- Get a free copy of the StockNews.com research report on Viracta Therapeutics (VIRX)
- Is the Electric Vehicle Movement Losing Steam?
- 3 High-Yield Banks Insiders Are Buying
- Will ChatGPT Be the Final Nail in the Coffin for Chegg?
- Is the Market Reacting Too Negatively to Pinterest Earnings?
- More Analysts Should See Energizer Holdings As A Buy: Here Is Why
Receive News & Ratings for Viracta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viracta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.